In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DexCom, Inc.

Latest From DexCom, Inc.

Allogene May Have Cracked The Off-The-Shelf CAR-T Problem

Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.

Commercial Clinical Trials

Caribou CEO On The Evolution Of CAR-T Treatment

Rachel Haurwitz, president and CEO of CRISPR-focused biotech Caribou, sat down with In Vivo to reflect on the thrill of the early days of CRISPR technology, Caribou’s second-generation approach, and the benefits of being a CEO with no prior corporate leadership experience.

C-Suite Speaks Interviews

Minute Insight: CMS Expands Medicare Coverage For CGM

The new policy expands coverage to more Medicare beneficiaries using insulin to treat diabetes, as well as people who need help managing hypoglycemia, and removes the prior requirement of multiple daily insulin injections.

Minute Insights Diabetic Care

FDA Clears Abbott’s Modified CGM For Automated Insulin Delivery Integration, Label Expansion

Abbott announced today it plans to integrate its FDA-cleared modified CGMs with insulin pump makers, including Tandem and Insulet, likely later this year.

FDA Approvals
See All

Company Information

  • Industry
  • Medical Devices
    • Monitoring Equipment & Devices
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
  • Other Names / Subsidiaries
    • SweetSpot Diabetes Care
    • TypeZero Technologies, LLC